Management team
Tom Collings
CEO and co-founder
Experienced team builder and leader of large, complex medical device development programs including at Cambridge Consultants. Over 15 years specialising in medical technology and healthcare.
Fiona Karet PhD FRCP FMedSci
Chief Medical Officer and co-founder
Extensive experience of patient management and research and strong links with renal patient groups. Professor of Nephrology, University of Cambridge and Consultant in Renal Medicine at Addenbrooke's Hospital
Tanya Hutter PhD
Chief Technology Officer and co-founder
Medical sensor expert, inventor of multiple patents, co-founder of SensorHut, Director of Women Ahead of Their Time. Assistant Professor at The University of Texas at Austin
Liz Norgett PhD
Chief Scientific Officer and co-founder
Expert in potassium disorders and skilled scientist with particular expertise in surface sensing chemistry and electrochemistry. Previous role as a Research Associate at The University of Cambridge
Board of directors
Ken Galbraith
Chair of the Board
Experienced biotechnology entrepreneur with almost 35 years of experience as an executive, director, investor and advisor in the North American and European medtech and biotechnology industry. Chair and CEO, Zymeworks; Director, Profound Medical
Ranndy Kellogg
Director
Experienced company builder focused on the transformative evolution of technology, data and services for greater patient-to-physician connection and improved outcomes. President and CEO, Omron Healthcare; Director, AliveCor
Amanda Wooding
Investor Director
Life sciences focused developer of businesses. Deputy Head of Life Sciences at Cambridge Enterprise specialising in commercialising technology and creating companies
Peter McPartland
Investor Director for Martlet Capital
Career background in institutional life sciences venture capital including former co-founder and General Partner of SV Health Investors. Peter has been involved in over 30 start-up and early stage businesses
Caroline Savage
Investor Director for Kidney Research UK
Trustee of Kidney Research UK and former Chair of Nephrology at University of Birmingham. Former VP and Head of the early development Experimental Medicine unit at GSK
Advisory board
Dr Fred Finkelstein
Clinical Professor of Medicine at Yale University and past Chair of the CME Program for the International Society of Nephrology. He has received several awards including the J. Michael Lazarus Distinguished Award (2015), the Karl Nolph Lifetime Achievement Award in Peritoneal Dialysis (2016) and the Oreopolous Award from the International Society of Peritoneal Dialysis (2020)
Dr Andrew Frankel
Consultant nephrologist at Imperial College Healthcare NHS trust. He has experience in managing all aspects of kidney disease, with a particular interest in relation to the management of cardio-renal metabolic disorders including the management of diabetes in the context of kidney disease. Joint editor of the UK Kidney Association guidelines on the use of SGLT2I in adults with chronic kidney disease.
Bill Moffitt
Accomplished chief executive and board chair with a distinguished track record in the healthcare industry. Led i-STAT Corporation, developing the blood analyser that pioneered portable point-of-care blood testing, from research stage to IPO then acquisition by Abbott for $400M. Most recently he served as President and CEO of Nanosphere along with Board positions at Base4 Innovation and Momentum Bioscience.